Sickle cell anaemia

8 trials 4 recruiting MedDRA PT
8 Registered trials
4 Recruiting
4 Unique sponsors
6 Unique IMPs
5 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 1
B Haematology (ATC B) 5
N Neurology/Psychiatry (ATC N) 1
V Various (ATC V) 1
— ATC code not specified 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 5 substances
Alkylating agent 1 substance
Phase III: 4 Phase II: 1 Phase IV: 2 Phase I (First in Human): 1

Filter these 8 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 8 trials

Phase III

4 trials
  • Vertex Pharmaceuticals Inc. Commercial
    BUSULFAN; EXAGAMGLOGENE AUTOTEMCEL; PLERIXAFOR
    2023-503247-34-00 2 countries n=5 Orphan
    Pending
  • Vertex Pharmaceuticals Inc. Commercial
    EXAGAMGLOGENE AUTOTEMCEL
    2024-512654-19-00 3 countries 2020 n=37 Orphan
    Recruiting
  • Vertex Pharmaceuticals Inc. Commercial
    EXAGAMGLOGENE AUTOTEMCEL
    2024-513978-22-00 2 countries 2022 n=4 Orphan
    Recruiting
  • Vertex Pharmaceuticals Inc. Commercial
    EXAGAMGLOGENE AUTOTEMCEL
    2024-514641-12-00 2 countries 2022 n=6 Orphan
    Recruiting

Phase II

1 trial
  • Assistance Publique Hopitaux De Paris Academic
    VOXELOTOR
    2024-513096-41-00 1 country 2022 n=35 Orphan
    Ended

Phase IV

2 trials
  • Centre Hospitalier Regional Universitaire De Tours Academic
    IOHEXOL; MORPHINE HYDROCHLORIDE
    2024-511985-34-00 1 country 2026 n=100
    Recruiting
  • CHU Saint Pierre Academic
    IMP not specified
    2025-523777-41-01 1 country n=40
    Pending

Phase I (First in Human)

1 trial
  • Vertex Pharmaceuticals Inc. Commercial
    EXAGAMGLOGENE AUTOTEMCEL
    2024-516067-83-00 2 countries 2019 n=9 Orphan
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Vertex Pharmaceuticals Inc. Commercial 5 Phase III, Phase I (First in Human) 3
Assistance Publique Hopitaux De Paris Academic 1 Phase II 0
Centre Hospitalier Regional Universitaire De Tours Academic 1 Phase IV 1
CHU Saint Pierre Academic 1 Phase IV 0
New trials by year
2019
1
2020
1
2022
3
2026
1
← All indication landscapes